Consumers and Providers Face Biosimilar Knowledge Hurdles

July 07, 2025

Significant knowledge gaps about biosimilars persist among consumers and healthcare professionals, hindering their adoption and potential benefits in health care.

Australian Patients With IBD Switched to Biosimilar Infliximab Maintain Long-Term Persistence

July 05, 2025

The Top 5 Biosimilar Articles for the Week of June 30

July 04, 2025

Biosimilar SB12 Matches Eculizumab in PNH Treatment Across Diverse Patient Groups

July 03, 2025

Biosimilars Rheumatology Roundup: June 2025

July 01, 2025

FDA Approves 10th Adalimumab Biosimilar, Simlandi

February 24th 2024

By Skylar Jeremias

Article

After receiving 3 complete response letters, Alvotech has officially received US approval for its adalimumab biosimilar (AVT02; Simlandi), making it the first approval for the company, the 10th biosimilar to reference Humira, and the third interchangeable adalimumab biosimilar.

The Top 5 Biosimilar Articles for the Week of February 19

February 23rd 2024

By Cameron Santoro

Video

Here are the top 5 biosimilar articles for the week of February 19, 2024.

Celltrion, Samsung Bioepis Unveil New Biosimilar Data in CD, UC at ECCO 2024

February 23rd 2024

By Skylar Jeremias

Article

At the Congress of European Crohn’s and Colitis Organisation (ECCO), Celltrion and Samsung Bioepis presented new finding from their respective biosimilar analyses, demonstrating positive safety and efficacy measures for the biosimilars as treatments for Crohn disease (CD) and ulcerative colitis (UC).

Adalimumab Treatment May Impact Antibody Levels After COVID-19 Vaccination

February 22nd 2024

By Skylar Jeremias

Article

A study investigating SARS-CoV-2 antibody levels after treatment with reference or biosimilar adalimumab found significant decreases in antibody levels in those receiving biologic therapy compared with those who did not.

Eye on Pharma: VA Picks Hadlima; Biocon, Sandoz Partnership; A Stelara Settlement Abroad

February 21st 2024

By Skylar Jeremias

Article

The US Department of Veterans Affairs (VA) has chosen to replace Humira (adalimumab) with Organon’s biosimilar version on its national formulary; Biocon Biologics and Sandoz announce a new partnership in Australia for 2 biosimilars; Alvotech settles with Johnson & Johnson over its biosimilar to Stelara (ustekinumab) for the European and Canadian markets.

Biosimilar HLX01 Demonstrates Bioequivalence With Rituxan in DLBCL

February 20th 2024

By Cameron Santoro

Article

A large Chinese study found that HanliKang (HLX01), a biosimilar rituximab, had similar overall survival and progression-free survival rates to the reference product (Rituxan) in patients with diffuse large B-cell lymphoma (DLBCL).

BioRationality: Biosimilar Steaks Turn into $3 Billion Mistakes

February 19th 2024

By Sarfaraz K. Niazi, PhD

Article

Similar to his piece on biosimilar whiskeys, Sarfaraz K. Niazi, PhD, takes on biosimilar steaks, which could be made using bioreactors to make affordable beef without harming animals, in his latest column.

Exploring the Biosimilar Horizon: Julie Reed's Predictions for 2024

February 18th 2024

By Skylar Jeremias

Podcast

On this episode of Not So Different, Julie Reed, executive director of the Biosimilars Forum, returns to discuss her predictions for the biosimilar industry for 2024 and beyond as well as the impact that the Forum's 4 new members will have on the organization's mission.

Summary of VOLTAIRE-X Study Explains Decision Behind Cyltezo Interchangeability

February 17th 2024

By Deana Ferreri, PhD

Article

Cyltezo (adalimumab-adbm) was the first adalimumab biosimilar—and second biosimilar overall—to receive an interchangeability designation from the FDA.

Biosimilar Substitution Within OCM Could Result in Lower Total Cost of Care

February 16th 2024

By Skylar Jeremias

Article

Researchers found that the total cost of care per oncology episode was significantly lowered when biosimilar substitution was implemented in Medicare’s Oncology Care Model (OCM), suggesting that biosimilar uptake can serve as a critical tool to mitigate risk and improve financial performance for providers.